Volume 11, Number 10—October 2005
Methicillin-resistant Staphylococcus aureus Necrotizing Pneumonia
Highlight and copy the desired format.
|EID||Monaco M, Antonucci R, Palange P, Venditti M, Pantosti A. Methicillin-resistant Staphylococcus aureus Necrotizing Pneumonia. Emerg Infect Dis. 2005;11(10):1647-1648. https://dx.doi.org/10.3201/eid1110.050776|
|AMA||Monaco M, Antonucci R, Palange P, et al. Methicillin-resistant Staphylococcus aureus Necrotizing Pneumonia. Emerging Infectious Diseases. 2005;11(10):1647-1648. doi:10.3201/eid1110.050776.|
|APA||Monaco, M., Antonucci, R., Palange, P., Venditti, M., & Pantosti, A. (2005). Methicillin-resistant Staphylococcus aureus Necrotizing Pneumonia. Emerging Infectious Diseases, 11(10), 1647-1648. https://dx.doi.org/10.3201/eid1110.050776.|
To the Editor: Methicillin-resistant Staphylococcus aureus (MRSA) strains account for >40% of all hospital-acquired S. aureus infections in Italy (1). Although cases of community-acquired MRSA (CA-MRSA) infections have been reported in recent years (2), these isolates have not been characterized for Panton-Valentine leukocidin (PVL) (3); therefore, the presence of isolates with the typical characteristics of CA-MRSA (4) in Italy remains unknown.
At the beginning of April 2005, a 37-year-old woman was admitted to the University Hospital Policlinico in Rome because of fever, cough, and headache. Her medical history was unremarkable. She was a teacher in a school for foreign students in Rome, smoked 3 cigarettes per day for 15 years, and reported no recent travel abroad. Her 5-year-old daughter had influenzalike symptoms in the previous week. At hospital admission, her temperature was 39°C, heart rate was108 beats/min, respiratory rate was 32 breaths/min, and blood pressure was 105/70 mmHg. Arterial blood gas analysis showed mild hypoxemia and hypocapnia (PaO2 73 mm Hg and PaCO2 34 mm Hg on room air). Leukocyte count was 24,360 cells/μL (81% polymorphonuclear cells), and platelet count was 506,000/μL. Chest radiograph showed infiltrates in the right upper and lower lobes and left lower lobe. Empiric treatment with clarithromycin and ceftriaxone was started, but the patient's clinical conditions did not improve. Culture of sputum samples obtained at admission yielded growth of MRSA. Computed tomographic scan showed multiple lung cavitary lesions, indicating necrotizing pneumonia. On day 3 of admission, antimicrobial drug therapy was changed to linezolid (600 mg 2 times a day). Fever resolved, and the patient's condition rapidly improved. The patient was discharged after 14 days of linezolid treatment. At discharge, leukocyte count was 6,040 cell/μL (58% polymorphonuclear cells), and arterial blood gas analysis showed PaO2 of 88 mm Hg.
The MRSA isolate from sputum was susceptible to all the non–β-lactam antimicrobial drugs tested, including erythromycin, clindamycin, ciprofloxacin, tetracycline, kanamycin, and fusidic acid. With established molecular methods, the isolate was found to harbor SCCmec type IV (5); lukS and lukF, the genes coding for the 2 subunits of the PVL toxin; and hlg, the γ-hemolysin gene (3). The genetic background of the isolate was determined by multilocus sequence typing (MLST) (6) and sequence typing of the tandem repeat region of protein A gene (spa typing) (7). Results showed that the isolate belonged to ST30 according to the MLST database (http://saureus.mlst.net), and spa typing, analyzed by the Ridom Staphtype software (http://www.ridom.de), indicated a novel spa type, to which type 755 was assigned. ST30, 1 of 6 clones more commonly associated with PVL-positive CA-MRSA (4), is designated also the southwest Pacific (SWP) clone, because of the area in which it circulates. Recently, the SWP clone has caused CA-MRSA infections in northern European countries (England, Scotland, the Netherlands, Sweden, and Latvia) (8,9). Molecular analysis suggests that the SWP clone has evolved from a methicillin-susceptible clone of S. aureus, termed phage type 80/81, that was pandemic in the 1950s and considered to be unusually virulent and transmissible (8). In fact, strains belonging to phage type 80/81 carry the PVL gene and appear to have subsequently acquired methicillin resistance through horizontal transfer of SCCmec type IV. The spa type of the Italian isolate comprises 7 nucleotide repeats, indicated by XJ4AKAOM in the alphabetical code. This repeat sequence differs from that of the classical SWP clone, indicated by XKAKAOMQ (8), by only 1 bp in the second repeat and loss of the last Q repeat. In spite of these differences, the spa type is in substantial agreement with the MLST result and indicates that the Italian isolate is either a descendent or a local variant of the SWP clone. The most common clone of CA-MRSA described in Europe is ST80, spa type 44. CA-MRSA belonging to ST80 tend to be more antimicrobial drug resistant than isolates belonging to other clones (4). Resistance to fusidic acid, typical of ST80, has been proposed as a marker for CA-MRSA in Europe (10). In light of our finding, we cannot rely on resistance to fusidic acid to screen for PVL-producing CA-MRSA in our country.
To our knowledge, this is the first report from Italy of necrotizing pneumonia caused by PVL-positive CA-MRSA. The presentation was typically that of a severe pneumonia that occurred in a previously healthy, young adult with no risk factors for MRSA acquisition, as described in other cases (11). This is also the first report of a SWP clone isolate in southern Europe; if the strain is circulating in Italy or is occasionally imported from the SWP area, whether our patient acquired it through contact with a foreign contact remains unknown.
- European Antimicrobial Resistance Surveillance System. EARSS Annual Report 2003. [cited 2005 Aug 16]. Available from http://www.earss.rivm.nl
- Pistella E, Campanile F, Bongiorno D, Stefani S, Di Nucci GD, Serra P, Successful treatment of disseminated cerebritis complicating methicillin-resistant Staphylococcus aureus endocarditis unresponsive to vancomycin therapy with linezolid. Scand J Infect Dis. 2004;36:222–5.
- Lina G, Piemont Y, Godail-Gamot F, Bes M, Peter MO, Gauduchon V, Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin Infect Dis. 1999;29:1128–32.
- Vandenesch F, Naimi T, Enright MC, Lina G, Nimmo GR, Heffernan H, Community-acquired methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes: worldwide emergence. Emerg Infect Dis. 2003;9:978–84.
- Oliveira DC, de Lencastre H. Multiplex PCR strategy for rapid identification of structural types and variants of the mec element in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2002;46:2155–61.
- Enright MC, Day NPJ, Davies CE, Peacock SJ, Spratt BG. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J Clin Microbiol. 2000;38:1008–15.
- Harmsen D, Claus H, Witte W, Rothganger J, Claus H, Turnwald D, Typing of methicillin-resistant Staphylococcus aureus in a university hospital setting by using novel software for spa repeat determination and database management. J Clin Microbiol. 2003;41:5442–8.
- Robinson DA, Kearns AM, Holmes A, Morrison D, Grundmann H, Edwards G, Re-emergence of early pandemic Staphylococcus aureus as a community-acquired methicillin-resistant clone. Lancet. 2005;365:1256–8.
- Vandenesch F, Etienne J. How to prevent the transmission of MRSA in the open community? Euro Surveill [serial on the Internet]. 2004 Nov [cited 2005 Aug 10]. Available from http://www.eurosurveillance.org/em/v09n11/0911-221.asp
- Witte W, Braulke C, Cuny C, Strommenger B, Werner G, Heuck D, Emergence of methicillin-resistant Staphylococcus aureus with Panton-Valentine leukocidin genes in central Europe. Eur J Clin Microbiol Infect Dis. 2005;24:1–5.
- Francis JS, Doherty MC, Lopatin U, Johnston CP, Sinha G, Ross T, Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes. Clin Infect Dis. 2005;40:100–7.
Please use the form below to submit correspondence to the authors or contact them at the following address:
Annalisa Pantosti, Dipartimento di Malattie Infettive, Parassitarie ed Immunomediate, Istituto Superiore di Sanità, Viale Regina Elena 299, 00161 Rome, Italy; fax: 39-06-4938-7112
Comment submitted successfully, thank you for your feedback.
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
- Page created: February 22, 2012
- Page last updated: February 22, 2012
- Page last reviewed: February 22, 2012
- Centers for Disease Control and Prevention,
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
Office of the Director (OD)